Intellizence Blog Mergers & Acquisitions by Top Biotechnology Companies – 2024

The biotechnology sector has witnessed several major acquisitions in 2024, highlighting a robust trend in mergers and acquisitions. Leading biotech and pharmaceutical giants are reshaping the healthcare landscape by acquiring innovative startups and clinical-stage companies. These strategic acquisitions accelerate the development of cutting-edge treatments and expand their expertise across various medical fields. Following are the top Mergers & Acquisitions (M&A) deals announced by top biotechnology companies in 2024. The data is curated from the Intellizence mergers & acquisitions Dataset.      AstraZeneca Fusion Pharmaceuticals, March 2024, $2.4B:  AstraZeneca acquired Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates (RCs), for $2.4 billion. This acquisition will help enhance AstraZeneca’s oncology portfolio by adding Fusion’s innovative RC pipeline, notably FPI-2265, a potential metastatic castration-resistant prostate cancer (mCRPC) treatment. The acquisition was completed in June 2024, Amolyt Pharma, March 2024, $1.05B: AstraZeneca acquired Amolyt Pharma, a clinical-stage biotechnology company specializing in treatments for rare endocrine diseases. The deal was valued at $1.05 billion and completed in July 2024, integrating Amolyt Pharma into AstraZeneca’s Alexion Rare Disease division.   Abbvie Landos Biopharma, May 23, 2024, $200M: AbbVie acquired Landos Biopharma,  a clinical-stage biopharmaceutical company focused on developing novel, oral therapeutics for patients with autoimmune […] The post Mergers & Acquisitions by Top Biotechnology Companies – 2024 first appeared on Intellizence.